PharmAust Drug Shows 91% Increase in MND/ALS Survival
Pharmaust Limited (AU:PAA) has released an update. PharmAust Limited has announced the completion of enrolment for their Open-Label Extension study...
Source: biztoc.com
Open Label Extension News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Open Label Extension. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Open Label Extension Today - Breaking & Trending Today
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing;...
Source: marketscreener.com
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular monoamine transporter 2 inhibitor for effective...
Source: marketscreener.com
Calliditas Therapeutics : May 23, 2024 Interim Report Q1 2024 (Presentation)
Q1 2024 REPORT May 23, 2024 Disclaimers Important information ...
Source: marketscreener.com
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
- Based on topline results from the Phase 3 PHOENIX trial of AMX0035 in ALS, Amylyx has started a process with the FDA and Health Canada of voluntarily discontinuing the marketing authorizations for...
Source: marketscreener.com